Zydus Cadila gets USFDA nod for blood pressure lowering drug

PTI New Delhi | Updated on May 13, 2019 Published on May 13, 2019

Representative image   -  Getty Images

The group now has 266 approvals and has filed over 350 ANDAs

Drug firm Zydus Cadila on Monday said it has received final nod from the US health regulator to market Chlorthalidone tablets, used to treat high blood pressure.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Chlorthalidone tablets in the strengths of 25 milligrams (mg) and 50 mg, the company said in a Bombay Stock Exchange (BSE) filing.

Chlorthalidone is used to treat high blood pressure (hypertension). It is also used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver or kidney disorders or edema caused by taking steroids or estrogen.

Zydus Cadila said the product will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 266 approvals and has filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.

Shares of Cadila Healthcare, the listed entity of the group, were trading 3.02 per cent lower at Rs 280.95 apiece on BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 13, 2019
This article is closed for comments.
Please Email the Editor